Form 990 for tax year 2022

Totals

Total revenue

$15,448,005

Total expenses

$14,306,730

Contributions and grants received

$58,500

Grants paid

$145,667

Program service revenue

$15,152,807

Investment income

$4,083

Other revenue

$232,615

Total assets, end of year

$4,082,175

Total liabilities, end of year

$13,328,762

Net assets or fund balances, end of year

-$9,246,587

Program services expenses (Part IX)

— not reported

Management and general expenses

— not reported

Fundraising expenses

— not reported

Program service expenses (Part III)

— not reported

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2022

• SEE SCHEDULE O:MEMBER SERVICES: THE ASSOCIATION WORKS TO SUPPORT AND EDUCATE ITS GLOBAL NETWORK OF NEARLY 45,000 ONCOLOGY PROFESSIONAL MEMBERS, MAINTAINING ONLINE FORUMS THAT ALLOW MEMBERS TO DISCUSS ISSUES OF PROFESSIONAL INTEREST, SUPPORTING INTERNATIONAL REGIONAL COUNCILS, AND RECRUITING MEMBERS FOR, AND TRACKING PARTICIPATION IN, VOLUNTEER ACTIVITIES RELATED TO THE ASSOCIATION, INCLUDING SERVING ON COMMITTEES.

• SEE SCHEDULE O:ACCREDITATION & CERTIFICATION: THE ASSOCIATION CONDUCTS AN ACCREDITATION PROGRAM THAT PROMOTES THE PRACTICE OF ITS MEMBERS BY MAINTAINING AND IMPROVING THE QUALITY OF MEDICAL CARE AVAILABLE TO THE PUBLIC AND MAINTAINING HIGH STANDARDS OF EXCELLENCE IN ONCOLOGY. THE QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI) CERTIFICATION PROGRAM ("QCP") PROVIDES A THREE-YEAR CERTIFICATION RECOGNIZING HIGH-QUALITY CARE FOR OUTPATIENT HEMATOLOGY-ONCOLOGY PRACTICES. THE QCP STANDARDS WERE ADAPTED FROM THE CHEMOTHERAPY ADMINISTRATION SAFETY STANDARDS CODEVELOPED BY ASCO AND THE ONCOLOGY NURSING SOCIETY (ONS). THEY ARE INTENDED TO REDUCE THE RISK OF ERRORS AND PROMOTING THE SAFE HANDLING OF CHEMOTHERAPY AGENTS. PARTICIPATING PRACTICES RECEIVE SITE SURVEYS BY EXPERIENCED ONCOLOGY PROFESSIONALS TO ASSESS COMPLIANCE WITH ALL QCP STANDARDS THROUGH INTERVIEWS, OBSERVATION, AND MEDICAL RECORD REVIEWS. PARTICIPANTS RECEIVE REPORTS DOCUMENTING THEIR LEVEL OF COMPLIANCE WITH EACH CERTIFICATION STANDARD AND MAKING RECOMMENDATIONS OR REQUIREMENTS FOR IMPROVED CARE. QCP CERTIFICATION RECOGNIZES HIGH PERFORMING PRACTICES AND IS NOT REQUIRED FOR ANY PROFESSIONAL LICENSING, NOR IS IT REQUIRED OF THE ASSOCIATION'S MEMBERS. 320 HEMATOLGY-ONCOLOGY PRACTICES WERE ACTIVELY CERTIFIED IN 2022.

• SEE SCHEDULE O:ADVOCACY: THE ASSOCIATION'S ADVOCACY WORK FOCUSES ON ASSURING HIGH-QUALITY CARE FOR ALL PATIENTS WITH CANCER. WORKING WITH VOLUNTEER MEMBERS AND AFFILIATED STATE AND REGIONAL ONCOLOGY SOCIETIES, ASCO ENGAGES WITH THE ADMINISTRATION, CONGRESS, AND STATE LAWMAKERS TO ADDRESS ISSUES OF CRITICAL IMPORTANCE TO CANCER CARE AND RESEARCH. THE ASSOCIATION'S ADVOCACY PORTFOLIO INCLUDES CLINICAL RESEARCH, INSURANCE COVERAGE FOR CANCER CARE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST AND ACCESS, SURVIVORSHIP, AND CANCER PREVENTION. ADVOCACY ACTIVITIES INCLUDE TRACKING, ANALYZING, AND INFLUENCING PENDING LEGISLATION AND REGULATIONS, AND EDUCATING BOTH MEMBERS AND POLICYMAKERS ABOUT THE IMPACT OF POLICY ON CANCER PATIENTS, CLINICIANS, AND CLINICAL RESEARCH. IN 2022, THE ASSOCIATION WAS SUCCESSFUL IN ITS EFFORTS TO OBTAIN INCREASED FUNDING FOR CANCER RESEARCH, WITH A $2.5 BILLION NIH FUNDING INCREASE OVER FY22 AND A $408 MILLION NCI FUNDING INCREASE OVER FY22, INCLUDING FULL FUNDING FOR THE FINAL YEAR OF THE CANCER MOONSHOT. ADDITIONALLY, THE FISCAL YEAR 2023 SPENDING PACKAGE PASSED BY CONGRESS REDUCED THE 4.47% CUT IN THE MEDICARE PHYSICIAN FEE SCHEDULE FINAL RULE BY 2.5%, LEADING TO A FINAL ESTIMATED CUT OF APPROXIMATELY 2% FOR 2023; WAIVED THE 4% MEDICARE STATUTORY PAY-AS-YOU-GO (PAYGO) CUT FOR 2023 AND 2024; AND EXTENDED THE ADVANCED ALTERNATIVE PAYMENT MODEL BONUS, PROVIDING A 3.5% INCENTIVE PAYMENT (DOWN FROM 5%) FOR 2023. FINALLY, THE HOUSE OF REPRESENTATIVES PASSED PRIOR AUTHORIZATION LEGISLATION, HR 3173, THE IMPROVING SENIORS' TIMELY ACCESS TO CARE ACT, AND MORE THAN HALF THE SENATE COSPONSORED PRIOR AUTHORIZATION LEGISLATION, THE MOST EVER. IN THE STATES, STEP THERAPY LAWS UPDATED IN COLORADO, KENTUCKY, MASSACHUSETTS, AND TENNESSEE; PRIOR AUTHORIZATION LAWS PASSED IN MICHIGAN AND LOUISIANA; AND A COMBINED PRIOR AUTHORIZATION AND STEP THERAPY LAW WAS ENACTED IN PENNSYLVANIA. ADDITIONALLY, COPAY ACCUMULATORS BANS WERE ENACTED IN MAINE, WASHINGTON, AND DELAWARE. ASCO ALSO SUPPORTED FEDERAL AGENCY POLICIES THAT RESULTED IN EXPANDED ACCESS TO ACA MARKETPLACE HEALTH PLANS (CURRENTLY A 13% INCREASE IN ENROLLMENT THIS YEAR COMPARED TO LAST), EXPANDED ACCESS TO COLORECTAL SCREENING FOR MEDICARE BENEFICIARIES, AND FIXED A LOOPHOLE IN THE ACA THAT HAD PREVIOUSLY PRESENTED A BARRIER TO ACCESS FOR SOME FAMILY MEMBERS OF INDIVIDUALS WITH AVAILABLE EMPLOYER-SPONSORED COVERAGE.

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• REGENTS OF THE UNIVERSITY OF MICHIGAN

  $54,167

  CANCER RESEARCH

• FRIENDS OF CANCER RESEARCH

  $25,000

  CANCER RESEARCH

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC

  501(C)(3) · RESEARCH/EDUCATION · NY

• CONQUER CANCER FOUNDAITON OF ASCO

  501(C)(3) · GRANTS · VA

  Directly controlled by ASCO

• ASCO ASSOCIATION POLITICAL ACTION COMM

  527 · ADVOCACY · VA · controlled entity

  Directly controlled by ASCO ASSOC

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Provenance

Return type

form_990

Tax year

2022

Filed

7 November 2023

IRS schema version

2022v5.0

Source object

202313139349300201

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.